Initial assessments involved eight pairs of fresh tissue specimens from normal and ccRCC patients for qPCR and WB validation, revealing that both RNA and protein levels of EPHX2 were significantly reduced in tumor samples (Figures 3A, B). This evidence concerns the gene EPHX2 and nonpapillary renal cell carcinoma.